checkAd

     195  0 Kommentare Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate - Seite 3

    Contact Adamis

    Mark Flather
    Senior Director, Investor Relations
    & Corporate Communications
    Adamis Pharmaceuticals Corporation
    (858) 412-7951
    mflather@adamispharma.com


     

    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate - Seite 3 SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) - Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHI high dose naloxone injection …